24 citations
,
November 2013 in “British Journal of Dermatology” This study found that chemotherapy in female breast cancer patients caused significant early hair loss, which began to recover three months after completion, whereas tamoxifen did not affect hair growth.
1 citations
,
May 2025 in “BMC Cancer” In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.
February 2024 in “PloS one” This study found that certain nutraceuticals did not interfere with tamoxifen's inhibition of estrogen in breast cancer cells and may enhance its effects, suggesting potential as an adjuvant therapy for hair loss in patients undergoing endocrine therapy.
68 citations
,
January 2013 in “BMC Pharmacology and Toxicology” This study found that glibenclamide exhibited a cytostatic effect on MDA-MB-231 breast cancer cells, potentially mediated through K ATP channels, and enhanced the antiproliferative impact of doxorubicin.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” This study explored the effects of various nutraceutical ingredients on breast cancer cell lines but found no conclusive information regarding their interaction with tamoxifen therapy.